Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: Pharmacology of the carbonyl and ethanolamide groups

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 59, Issue 2, 1998, Pages 111-118

  Berglund, B A ^a   Boring, D L ^b,c   Wilken, G H ^a   Makriyannis, A ^d   Howlett, A C ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ANANDAMIDE DERIVATIVE; CANNABINOID RECEPTOR; CARBONYL DERIVATIVE; ETHANOLAMIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHYL GROUP; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CHIRALITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0031709221     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(98)90089-8     Document Type: Article

References (19)

1. Adams I. B., Ryan W, Singer M., Thomas B. F., Compton D. R., Razdan R. K., Martin B. R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Expt Ther 1995; 273: 1172-1181.
2. Boring D. L., Berglund B. A., Howlett A. C. Cerebrodiene, arachidonyl ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 207-210.
3. Edgemond W. S., Campbell W. B., Hillard C. J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 83-86.
4. Felder C. C., Briley E. M., Axelrod J., Simpson J. T., Mackie K., Devane W. A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal. PNAS 1993; 90: 7656-7660.
5. Howlett A. C., Evans D. M., Houston D. B. The cannabinoid receptor. In: Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Murphy L. L., Bartke A. (eds). Boca Raton: CRC Press; 35-72.
6. Koutek B., Prestwich G. D., Howlett A. C., Chin S. A., Salehani D., Akhavan N., Deutsch D. G. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994; 269: 22937-22940.
7. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997; 40: 659-667.
8. Pinto J. C., Potie F., Rice K. C., Boring D., Johnson M. R., Evans D. M., Wilken G. H., Cantrell C. H., Howlett A. C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994; 46: 516-522.
9. Abadji V., Lin S., Taha G., Griffin G., Stevenson L. A., Pertwee R. G., Makriyannis A. (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37: 1889-1893.
10. Khanolkar A. D., Abadji V., Lin S., Hill W. A. G., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 1996; 39: 4515-4519.
11. Cassel D., Selinger Z. Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim Biophys Acta 1976; 452: 538-551.
12. Howlett A. C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985; 27: 429-436.
13. Tong W., Collantes E. R., Welsh W. J., Berglund B. A., Howlett A. C. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis (CoMFA). J Med Chem 1998.
14. Thomas B. F., Adams I. B., Mascarella S. W., Martin B. R., Razdan R. K. Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem 1996; 39: 471-479.
15. Huffman J. W., Yu S., Showalter V., Abood M. E., Wiley J. L., Compton D. R., Martin B. R., Bramblett R. D., Reggio P. H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 1996; 39: 3875-3877.
16. Melvin L. S., Milne G. M., Johnson M. R., Subramaniam B., Wilken G. H., Howlett A. C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44: 1008-1015.
17. Deutsch D. G., Makriyannis A. Inhibitors of Anandamide Breakdown. NIDA Res Mono 1997; 173: 65-87.
18. Galiegue S., Sophie M., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., LeFur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
19. Reggio P. H., Seltzman H. H., Compton D. R., Prescott W. R., Jr. Martin B. R. Investigation of the role of the phenolic hydroxyl in cannabinoid activity. Mol Pharmacol 1990; 38: 854-862.